• Dr Reham M Dawood, Ghada Maher Salum, and Mai Abd El-Meguid.
• Department of Microbial Biotechnology, Genetic Engineering Division, National Research Centre, Giza, Egypt. Electronic address: rmhaemd@hotmail.com.
• Am. J. Med. Sci. 2022 Feb 1; 363 (2): 94-103.

AbstractThe current coronavirus disease outbreak of 2019 (COVID-19) has led to a global pandemic. The principal cause of mortality in COVID-19 is represented lung injury with the development of acute respiratory distress syndrome (ARDS). In patients with COVID-19 infection, liver injury or liver dysfunction has been reported. It may be associated with the general severity of the disease and serve as a prognostic factor for ARDS development. In COVID-19, the spectrum of liver damage may range from direct SARS-CoV-2 viral proteins, inflammatory processes, hypoxemia, the antiviral drugs induced hepatic injury and the presence of the preexisting liver disease. We highlight in this review important topics such as the epidemiological features, potential causes of liver injury, and the strategies for management and prevention of hepatic injury in COVID-19 patients.Copyright © 2021 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

11 keywords...

hide…